Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared With Placebo in Patients With Idiopathic Pulmonary Fibrosis and in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease

NCT05785624 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05785624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05785624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared With Placebo in Patients With Idiopathic Pulmonary Fibrosis and in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 26, 2023
Completion date
January 12, 2026
Enrollment
286 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis, systemic sclerosis with lung involvement